Featured Stories
US Backs Oral COVID-19 Therapies And ‘Next Pandemic’ Drug Discovery With $3.2bn
Aiming to mimic public-private COVID-19 vaccine success, the US NIH will fund pandemic drug research, including taking candidates up to Phase II.
Orphazyme Tumbles Back To Earth As FDA Rejects Arimoclomol
Following a week of "insane trading" which saw the Danish stock soar based on social media chatter, US regulators have surprised the firm and investors by issuing a complete response letter for arimoclomol for Niemann-Pick disease type C.
Should Global Pharmas Focus More On Korean Partners?
PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena.
Coronavirus Spotlight
Does New Study Question Need for Pediatric COVID-19 Vaccines?
A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Scrip Podcast
Recent Tweets from Scrip
Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
The 2021 Worldwide Pharma And Biotech R&D Scene
INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.
Pandemic Perspectives: China Vaccine Diplomacy - A World On Shots
Over 50 countries around the world are now receiving COVID-19 vaccine deliveries from China, totaling 3.3 million doses and counting so far. This Scrip infographic shows their locations, quantity of supplies and the developers involved.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Commercial
BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
BIO 2021 Notebook: Best Practices For Business Development
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.
Lupin’s US Advair Generic Plans Turn Awry As Celon Pact Nears End
Lupin’s plans for a US generic to GSK’s Advair Diskus have turned awry as its contract with Celon Pharma is close to being terminated. The company has focused on other respiratory drugs like generic ProAir and Fostair even as the revenue potential for Advair has been shrinking post Mylan’s launch.
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities
Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy & Regulation, Policy & Regulation
BIO 2021 Notebook: Biogen CEO On Corporate Responsibility
News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains.
BIO Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
BIO 2021 Notebook: A Breakthrough Year For Emerging Companies?
News and views from day two of the BIO Digital annual meeting include the increasing number of small companies driving US product approvals, the US FDA's Patrizia Cavazzoni on science vs. emotion at advisory committees and Merck & Co.'s Julie Gerberding on the need for continued HIV/AIDS research.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Blow For CureVac As COVID-19 Vaccine Hits 47% Efficacy
CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.
BIO Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.